Introduction/Background Human epididymis protein 4 (HE4) has been reported as a promising complement to CA125 in the assessment of the risk of malignancy in patients, diagnosed with pelvic mass. However, reference limits of HE4 do not provide clinically relevant discrimination between malignant and benign ovarian diseases. The clinical significance of well-known Risk of Ovarian Malignancy Algorithm (ROMA), which combines both HE4 and CA125, is still questionable. Recently, ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors implied that neither HE4 nor ROMA improve the discrimination between benign and malignant masses compared with CA125 alone.
Methodology An external validation of the new algorithm, named Risk of Ovarian Cancer Kazan Index (ROCK-I), will be presented. A comprehensive analysis of the performance of ROCK-I will be presented with the focus on clinical utility of adding HE4 to CA125 and ultrasound evaluation.
Results A comprehensive analysis of the performance of ROCK-I will be presented with the focus on clinical utility of adding HE4 to CA125 and ultrasound evaluation.
Conclusion HE4 is a useful compliment to expert ultrasound and CA125
Disclosures Authors has nothing to disclosure
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.